Patients who received @ of @ dosing regimens of evolocumab in the parent studies and received evolocumab + SOC in OSLER had persistent LDL-C reductions ( mean reduction , @ % -LSB- SE , @ % -RSB- at the end of the parent study versus @ % -LSB- SE , @ % -RSB- at @ weeks ; P = @ ) .